FIELD: medicine.
SUBSTANCE: present invention refers to immunology. What is presented is using Blinatumomab for producing a pharmaceutical composition for treating, relieving or eliminating acute lymphoblastic leukaemia (ALL) in children, wherein Blinatumomab transforms MRD (a minimal residual disease) - positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL.
EFFECT: using the invention provides transforming MRD-positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL at the molecular level that can find application in medicine in therapy of recurrent ALL in children.
23 cl, 5 dwg, 1 tbl, 1 ex
